Varubi (Rolapitant HCl) Patent Expiration, LOE Window & CMS Spending
Varubi (Rolapitant HCl) by Tersera Therapeutics: FDA Orange Book core substance LOE 2028-08-19 (last listed 2029-10-09), 0 AB generics, $533K 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Tersera Therapeutics |
| FDA Application & Pathway | N206500 (NDA) |
| Exclusivity / Cliff Horizon | Near-Term Cliff (2028-2030) |
| Core Active-Ingredient LOE Date | 2028-08-19 |
| Last Listed Patent or Exclusivity Date | 2029-10-09 |
| Orange Book Patents (*PED Extensions) | 7 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $533K |
| 2024 Medicare Part D Spend | $533K |
| 2024 Medicaid Spend | $0 |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |